[1]夏平,杨浩.炎症与心房颤动相关性的研究进展[J].心血管病学进展,2015,(5):637-641.[doi:10.3969/j.issn.1004-3934.2015.05.030]
　XIA Ping,YANG Hao.Research Progress of Inflammation Associated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(5):637-641.[doi:10.3969/j.issn.1004-3934.2015.05.030]
点击复制

炎症与心房颤动相关性的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2015年5期
页码:
637-641
栏目:
综述
出版日期:
2016-05-20

文章信息/Info

Title:
Research Progress of Inflammation Associated with Atrial Fibrillation
作者:
夏平; 杨浩
皖南医学院附属弋矶山医院心血管内科,安徽 芜湖 241000
Author(s):
XIA Ping; YANG Hao
Cardiology Department,Yijishan Hospital Affiliated with Wannan Medical College,Wuhu 241000, Anhui, China
关键词:
心房颤动;  炎症;  炎性介质;  抗炎药;  血栓
Keywords:
atrial fibrillation;  inflammation;  inflammatory markers;  anti-inflammatory drugs;  thrombogenesis
分类号:
R541.7
DOI:
10.3969/j.issn.1004-3934.2015.05.030
文献标志码:
A
摘要:
心房颤动(Af)是临床最常见的心律失常之一。目前对Af及其并发症(最重要是血栓形成)的有效治疗仍然是当前心律失常治疗中最薄弱的环节。Af的发病机制尚不完全明确。近年来大量临床和基础研究均提示炎症参与了Af的发生和发展。炎症与各种病理过程有关,如氧化应激、细胞凋亡、纤维化和促进Af基质形成。炎症还与内皮功能障碍、血小板活化、凝血酶联激活相关,这些均参与血栓形成过程。现对炎性介质及抗炎药物在Af中可能的作用机制及与Af的相关性综述如下。
Abstract:
Atrial fibrillation(Af)is the most common clinically relevant arrhythmia, however the methods available for treating Af and its complications(of which the most important is thrombogenesis), as well as for assessing Af risk and underlying pathophysiology, are largely limited. Emerging clinical and basic evidence suggests that inflammation may contribute to both the occurrence/maintenance of Af. Inflammation is suggested to be linked to various pathological processes that promote Af substrate formation such as oxidative stress, apoptosis and fibrosis. Inflammation has also been associated with endothelial dysfunction,platelet activation and coagulation cascade activation, leading to thrombogenesis. The role of inflammation and inflammatory biomarkers in the risk management and treatment of Af is reviewed in this article.

参考文献/References:

[1] Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation[J]. J Am Coll Cardiol,2012,60(22): 2263-2270.
[2] Andrade J, Khairy P, Dobrev D,et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features,epidemiology,and mechanisms[J]. Circ Res,2014,114(9): 1453-1468.
[3] Putko BN, Wang Z, Lo J, et al. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology[J]. PLoS One,2014,9(6):e99495.
[4] Maesen B, Nijs J, Maessen J,et al. Post-operative atrial fibrillation:a maze of mechanisms[J]. Europace,2012,14(2):159-174.
[5] Schiffrin EL. The immune system: role in hypertension[J]. Can J Cardiol,2013,29(5):543-548.
[6] Kristensen SL, Lindhardsen J, Ahlehoff O, et al. Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease:a nationwide study[J]. Europace,2014,16(4):477-484.
[7] Cianfrocca C, Loricchio ML, Pelliccia F, et al. C-reactive protein and left atrial appendage velocity are independent determinants of the risk of thrombogenesis in patients with atrial fibrillation[J]. Int J Cardiol,2010,142(1):22-28.
[8] Raviele A, Ronco F. Endothelial dysfunction and atrial fibrillation:what is the relationship[J]. J Cardiovasc Electrophysiol,2011,22(4):383-384.
[9] Wieberdink RG, van Schie MC, Koudstaal PJ, et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study[J]. Stroke,2010,41(10):2151-2156.
[10] Lim HS, Willoughby SR, Schultz C, et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm[J]. J Am Coll Cardiol,2013,61(8):852-860.
[11] Lim HS, Willoughby SR, Schultz C, et al. Successful catheter ablation decreases platelet activation and improves endothelial function in patients with atrial fibrillation[J]. Heart Rhythm,2014,11(11):1912-1918.
[12] Neumann FJ,Ott I,Marx N,et al.Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity[J]. Arterioscler Thromb Vasc Biol,1997,17(12):3399-3405.
[13] Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchows triad revisited[J]. Lancet,2009,373(9658):155-166.
[14] Chung MK,Martin DO,Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation[J]. Circulation,2001,104(24):2886-2891.
[15] Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation[J]. Circulation,2003,108(24):3006-3010.
[16] Psychari SN, Apostolou TS, Sinos L,et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation[J]. Am J Cardiol,2005,95(6):764-767.
[17] Watanabe E, Arakawa T, Uchiyama T,et al. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion[J]. Int J Cardiol,2006,108(3):346-353.
[18] Wu N, Xu B, Xiang Y, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis[J]. Int J Cardiol,2013,169(1):62-72.
[19] Marcus GM, Smith LM, Ordovas K, et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation[J]. Heart Rhythm,2010,7(2):149-154.
[20] Pinto A, Tuttolomondo A, Casuccio A, et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation(NVAF)[J].Clin Sci(Lond),2009,116(10):781-789.
[21] Liuba I,Ahlmroth H,Jonasson L,et al.Source of inflammatory markers in patients with atrial fibrillation[J]. Europace,2008,10(7):848-853.
[22] Li J, Solus J, Chen Q, et al. Role of inflammation and oxidative stress in atrial fibrillation[J]. Heart Rhythm,2010,7(4):438-444.
[23] Shroff GR, Orlandi QG. Letter by Shroff and Orlandi regarding article, “Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3(Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery)study”[J]. Circulation,2007,115(15):e404; author reply e405.
[24] Pena JM, MacFadyen J, Glynn RJ, et al. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial[J]. Eur Heart J,2012,33(4):531-537.
[25] Ho KM,Tan JA.Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery:a dose-response meta-analysis[J]. Circulation,2009,119(14):1853-1866.
[26] Harling L, Rasoli S, Vecht JA,et al. Do antioxidant vitamins have an anti-arrhythmic effect following cardiac surgery? A meta-analysis of randomised controlled trials[J]. Heart,2011,97(20):1636-1642.
[27] Rodrigo R, Korantzopoulos P, Cereceda M, et al. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement[J]. J Am Coll Cardiol,2013,62(16):1457-1465.
[28] Sakabe M, Shiroshita-Takeshita A, Maguy A, et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling[J]. Circulation,2007,116(19):2101-2109.
[29] Imazio M, Brucato A, Ferrazzi P, et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome(COPPS)atrial fibrillation substudy[J]. Circulation,2011,124(21):2290-2295.

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
　HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(5):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
　DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(5):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
　BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(5):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[4]阎萌,田芳,综述,等.程序性坏死与动脉粥样硬化[J].心血管病学进展,2016,(2):139.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.011]
　YAN Meng,TIAN Fang,TIAN Ye.Necroptosis and Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(5):139.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.011]
[5]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
　ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[6]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
　ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[7]陈芡茹,综述,叶飞,等.心血管疾病治疗新目标:脂蛋白相关磷脂酶A2[J].心血管病学进展,2016,(2):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
　CHEN Qianru,YE Fei.Novel Therapeutic Target of Cardiovascular Disease:Lipoprotein Associated Phospholipase A2[J].Advances in Cardiovascular Diseases,2016,(5):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
[8]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
　LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(5):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[9]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
　HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[10]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
　WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]

备注/Memo

备注/Memo:
作者简介:夏平(1988—),硕士研究生,主要从事心血管内科研究。Email:462700815@qq.com 通信作者:杨浩(1966—),副教授,主任医师,主要从事电生理及射频消融研究。Email:yjsxnyh@sina.com
更新日期/Last Update: 2016-05-20